Brokerage firm Jefferies Maintains its rating on BioCryst Pharmaceuticals(NASDAQ:BCRX). In a research note issued to the investors, the brokerage major Raises the price-target to $3.00 per share. The shares have been rated Hold. The rating by Jefferies was issued on Aug 5, 2016.
In a different note, On Aug 4, 2016, JMP Securities said it Downgrades its rating on BioCryst Pharmaceuticals. The shares have been rated ‘Market Perform’ by the firm.
BioCryst Pharmaceuticals (BCRX) shares turned negative on Wednesdays trading session with the shares closing down -0.06 points or -1.37% at a volume of 13,23,486. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.4. The peak price level was also seen at $4.4 while the days lowest was $3.95. Finally the shares closed at $4.31. The 52-week high of the shares is $14 while the 52-week low is $1.63. According to the latest information available, the market cap of the company is $318 M.
BioCryst Pharmaceuticals(BCRX) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $4.79M. Analysts had an estimated revenue of $3.92M. Earnings per share were $-0.22. Analysts had estimated an EPS of $-0.26.
Several Insider Transactions has been reported to the SEC. On Dec 22, 2015, Thomas R Ii Staab (Senior Vice President and CFO) sold 3,052 shares at $10.86 per share price.Also, On Jun 22, 2015, William P Sheridan (Senior VP – CMO) sold 70,389 shares at $15.05 per share price.On Jun 22, 2015, Alane P Barnes (VP, General Counsel & Corp Sec) sold 3,000 shares at $15.00 per share price, according to the Form-4 filing with the securities and exchange commission.
BioCryst Pharmaceuticals Inc. (BioCryst) is a biotechnology company. The Company designs optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB BCX4161 BCX7353 and other second generation HAE compounds BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza in the United States as RAPIVAB in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.